ISB Gets $1.7M to Study Cancer Drug Resistance
systemsbiology.org/news/2015/02/09/isb-gets-1-7m-to-study-cancer-drug-resistance/
Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a tumor cell population to address the unmet need to understand how heterogeneity and subpopulation dynamics of tumor cell populations affect drug response.”
Learn more:
Cancer Treatment: A Systems Approach
New Principle of Chemo-Resistance Sheds Light on Cancer Evasiveness
Biggest Family Tree of Human Cells May Help Develop Cell-Replacement Therapies
Related Articles
-
The Cancer Paradox
ISB’s Dr. Sui Huang uses the theory of complex systems and applies it to cancer research. In this video Q&A, he discusses the cancer paradox and highlights the importance of understanding the mechanism of what cancer treatments can backfire in order to open a new avenue for therapy and treatments.
Read More -
Dr. Wei Wei Awarded CARE Grant
The Andy Hill Cancer Research Endowment (CARE) is a public-private partnership that supports cancer research in Washington state. CARE announced ISB Assistant Professor Dr. Wei Wei as a CARE Fund Distinguished Researcher and awarded him $500,000.
Read More -
ISB's Dr. Sui Huang Earns Funding to Tackle Cancer's Biggest Questions
ISB’s Professor Sui Huang, MD, PhD, has been announced by Cancer Research UK as a member of a global research team funded through its Grand Challenge competition — an international funding initiative that aims to answer some of the biggest questions facing cancer research.
Read More
-
ISB President Dr. Jim Heath Awarded $750,000 from Andy Hill Cancer Research Endowment
The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.
Read More -
New Principle for Eradicating Cancer: Leave No Dead Cells Behind
Dead cells, or cell debris, generated by treatments intended to eradicate tumor cells actually act as strong stimulators of tumor progression. The findings of ISB cancer biologist Sui Huang, his former mentee and longtime collaborator Dipak Panigrahy at Beth Isreal Deaconess Medical Center in Boston, and colleagues at Harvard Medical School were published in The Journal of Experimental Medicine.
Read More -
New Publication in Cell Systems
April 25, 2017 A Cell-Surface Membrane Protein Signature for Glioblastoma 3 bullets: Using integrated protein and gene expression data, ISB researchers developed a 33-gene signature for glioblastoma, an aggressive form of brain cancer. Glioblastoma gene signatures are associated with TGF-b signaling and cancer invasion. Researchers think that some of the glioblastoma gene signatures have the potential to be used as blood biomarkers for this aggressive cancer. Read the full summary…
Read More
-
New Baliga Lab Publication in Cell Systems
The Baliga Lab’s Dr. Christopher Plaisier was the lead author of the study “Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis” which published online in Cell Systems on July 14. Dr. Plaisier wrote a summary of the research: 3 Bullets: Using data from TCGA and ENCODE, ISB researchers developed integrative database and analysis platforms that provide insight about the underpinnings of glioblastoma multiforme. Researchers developed a…
Read More -
A Landscape of Pharmacogenomic Interactions in Cancer
The journal Cell published a study today (July 7) about the integrated analysis of drug response in 1,001 cancer cell lines. This study was undertaken by a large international group of researchers including ISB Senior Research Scientist Theo Knijnenburg. The researchers integrated heterogeneous molecular data of 11,215 tumors and 1,001 cell lines in order to study the drug response of these cell lines to 265 anti-cancer drugs. They uncovered numerous…
Read More -
New Publication in ‘Cancer Cell’
As part of The Cancer Genome Atlas project, the Shmuelvich Lab and colleagues published a paper in the journal Cancer Cell related to the rare cancer adrenocortical carcinoma. Read the summary: 3 Bullets: Adrenocortical carcinoma (ACC) is a rare, under-researched endocrine cancer with limited therapeutic options and overall poor outcome. TCGA researchers performed comprehensive analysis of 91 ACC samples to gain better understanding of potential genetic causes of the cancer….
Read More
-
Using Google Cloud Platform to Give Researchers Easier Access to Cancer Data
ISB’s Dr. Ilya Shmulevich attended Google Cloud Platform’s GCPNext conference in San Francisco and presented on ISB’s Cancer Genomics Cloud project. He explains how his team used GCP to create better access for a broad range of researchers to cancer genomics data (from The Cancer Genomics Atlas) and the tools with which to explore that data. Watch Dr. Shmulevich’s talk below.
Read More -
Event: Cancer Think Tank
Cure First is hosting the forum “Cancer Think Tank.” Speakers include ISB’s Dr. Ilya Shmulevich and Dr. Brady Bernard. Date: January 21, 2016 Time: 1-5:30 p.m. MED talks, breakout sessions, and panel discussion; 6-8 p.m. networking with wine and dinner Why: To jump start innovative collaborations in cancer research with the goal to submit proposals for funding to accelerate the discovery of new, less toxic and targeted therapies. Who: This…
Read More -
A Mixture of Markers from Two Distinct Cell Types Indicates Poor Prognosis in Breast Cancer
3 Bullets: Identifying the most aggressive cells in cancer (cancer stem cells) is essential for designing effective therapy and predicting patient outcomes. Using single-cell analysis techniques, researchers at ISB and Luxembourg Centre for Systems Biomedicine have identified the molecular signatures of two types of malignant breast tissue cells. Researchers found an interesting twist: the two cell types “cooperate” to increase malignancy potential and they promote a third hybrid stem-cell type….
Read More
-
Bio-Fiction Recap
On May 7, ISB hosted the first-ever screening of BIO·FICTION in North America. More than 120 people attended the event, which took place as part of the South Lake Union Art Walk. BIO·FICTION explores the emerging field of synthetic biology from different disciplinary angles including science and engineering, social science, cultural studies, amateur biology, filmmaking, art and design. The original program had presentations, panel discussions, do-it-yourself biology demos, performances, art…
Read More -
NIH-Led Effort – Including ISB – Launches Big Data Portal for Alzheimer’s Drug Discovery
The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies. The launch of the AMP Alzeheimers Disease Knowledge Portal is…
Read More -
ISB Innovations: Ultrasound-Based Tumor Biopsies
Name: John Chevillet, PhD Lab: Hood Research: I am trying to develop an ultrasound-based method to take a sample from a tumor, thus replacing needle biopsies. An ultrasound-based method would minimize complications, better diagnose cancers, and direct the use of targeted therapies for personalized medicine. Wish List: If I had $10,000, I could analyze the blood specimens we currently have for cancer dna to demonstrate what this method can tell…
Read More
-
ISB at Town Hall Seattle on March 18
Mark your calendars for 7:30 p.m. on March 18 to join ISB for a panel discussion about “Tipping Points in Environment and Climate.” The event takes place at Downstairs at Town Hall. Tickets are $5. Info: townhallseattle.org/event/isb-panel Panel description: So-called tipping points — sudden, large-scale environmental changes — are altering our ecosystem in non-intuitive ways that defy our sense of causation. Because the nature of these shifts makes them unexpected,…
Read More -
ISB Taps Kathy Scanlan as New Chief Operating Officer
ISB announces the appointment of Kathy Scanlan as chief operating officer. Scanlan’s leadership career has spanned government, nonprofits and sports, and includes serving as the Executive Vice-President of the 1990 Seattle Goodwill Games Organizing Committee and as President of USA Gymnastics. Through Scanlan Consulting, her assignments have included working closely with the Washington State Legislature on ferry and transportation issues; strategic and business planning for museums, park facilities, and global health/discovery science…
Read More -
ISB’s Women in Oceanography
Photos above: (Left) Anne Thompson and (right) Mόnica Orellana as featured in “Women in Oceanography: A Decade Later.” BY ISBUSA Two of ISB’s senior research scientists are featured in the second edition of “Women in Oceanography.” Dr. Mόnica Orellana and Dr. Anne Thompson, both of the Baliga Lab, share their stories about what inspired their careers in oceanography and some of their thoughts about working in the field. The inaugural issue…
Read More
-
ISB Announces Cynthia Shumate as Chief Legal Officer
ISB announces the appointment of Cynthia Shumate as the chief legal officer and chief compliance officer. She also will serve as the secretary of the ISB’s board of directors. Shumate’s has had a long career as the CLO or CCO of several biotechs, including including a number of notable private corporations including ZetaRx Biosciences (now Juno Therapeutics) and Allozyne, as well as the public company PDL BioPharma. She is a…
Read More -
Cancer Genomics Cloud: ISB and Google Featured in MIT Tech Review
(Above illustration from MIT Technology Review.) MIT Technology Review published an article about the launch of Google Genomics and included a mention of ISB’s new Cancer Genomics Cloud project. ISB received an up-to $6.5 million, two-year NIH contract in collaboration with Google and SRA International. From the MIT Technology Review article: The idea is to create “cancer genome clouds” where scientists can share information and quickly run virtual experiments as…
Read More -
How Physics and Thermodynamics Help Assess DNA Defects in Cancer
3 Bullets: ‘Big data’ cancer research has revealed a new spectrum of genetic mutations across tumors that need understanding. Existing methods for analyzing DNA defects in cancer are blind to how those mutations actually behave. ISB scientists developed a new approach using physics- and structure-based modeling to systematically assess the spectrum of mutations that arise in several gene regulatory proteins in cancer. By Jake Valenzuela and Justin Ashworth A significant…
Read More
-
New Details on Thyroid Cancer May Lead to More Precise Therapies
3 Bullets: Papillary thyroid cancer represents 80 percent of all thyroid cancer cases. Integrative analysis resulted in the detection of significant molecular alterations not previously reported in the disease. ISB researchers identified microRNAs which may lead to more precise therapy. By Lisa Iype Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 80 percent of all cases. As part of The Cancer Genome Atlas (TCGA)…
Read More -
It’s Easier to Go ‘Viral’ When Your Partner Happens to be Google
By ISBUSA Since we announced that we got a $6.5 million contract from NCI to develop the Cancer Genomics Cloud pilot project, we’ve gotten some great press from around the world. It doesn’t hurt that one of our partners is Google, of course. Here are some of the headlines from around the world: Puget Sound Business Journal: Cancer in the cloud: Institute for Systems Biology teams up with Google NBCNews.com:…
Read More -
ISB Awarded $6.5 Million NIH Contract to Develop ‘Cancer Genomics Cloud’ with Google and SRA International
PRESS RELEASE Institute for Systems Biology (ISB) has received a $6.5 million, up to two-year, federally funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). ISB is one of three organizations awarded a contract by NCI to develop a cloud-based platform that will serve as a large-scale data repository and provide the computational infrastructure necessary to carry out cancer genomics research at unprecedented scales. ISB’s Shmulevich…
Read More
-
ISB Gets $2.3 million NIH Grant to Use Single-Cell Technology to Fight Cancer
Pictured above: Dr. Qiang Tian, left, and Dr. Edward Lin, right, discuss single-cell analysis technologies developed at Institute for Systems Biology in Seattle. September 22, 2014 – ISB has received a $2.3 million NIH grant over four years in response to NCI’s “Provocative Questions” Initiative. The project will apply ISB’s most advanced single-cell omics technologies to an innovative clinical trial for colorectal cancer (ADAPT). Principal investigator Qiang Tian, MD, PhD,…
Read More -
New Structural Map Helps To Understand Aggressive Tumors
3 Bullets: Aggressive tumor growth is linked to high activity of a macromolecular assembly called RNA polymerase I. ISB and FHCRC researchers collaborate to map the architecture of the assembly using a powerful crosslinking-mass spectrometry (CXMS) technology. Structural maps provide important insights into therapeutic targets for cancer treatment. By Mark Gillespie Rapidly growing tumor cells require large amounts of protein for their survival. This increased protein synthesis, or translation, can…
Read More -
ISB Researchers Help Identify Four New Subtypes of Gastric Cancer That May Lead to New Targeted Treatments
3 Bullets: Gastric cancer has a high mortality rate, but current classification systems haven’t been effective in helping to identify subtypes relevant for treatment of the disease. TCGA researchers have integrated molecular data from 295 stomach tumors and have discovered four subtypes of gastric cancer. Stratification of patients into these four subtypes paves the way for the development of new personalized therapies. By Theo Knijnenburg Gastric cancer is among the…
Read More
-
ISB’s 2013 Annual Report is Now Available
Institute for Systems Biology has a dizzying breadth of research projects. But when we talk about what we do, it’s how we do it that matters most. The systems approach that we pioneered and exemplify continues to distinguish our ability to tackle the most complex biological and environmental challenges today. Because of how we apply our hallmark collaborative, cross-disciplinary and integrative approach, our collective success is greater than the sum…
Read More -
3-Minute Science: ISB and Seattle BioMed Hold Annual Lightning Talks
Photo: Theo Knijnenburg, a research scientist in ISB's Shmulevich Lab, presentaed a summary of his work related to gene mutations and cancer drug sensitivity. Systems biology is about the culture as much as a scientific approach. ISB and Seattle BioMed have an inter-institutional agreement that enables the collective to benefit from shared knowledge and technology resources. For the second consecutive year, we held Lightning Talks (June 12) to allow researchers…
Read More -
LAB NOTEBOOK: Evolution Beyond Darwin
(Photo: Dr. Sui Huang presenting during an ISB systems biology discussion group on May 15, 2014.) LAB NOTEBOOK: At ISB, we hold systems biology discussion groups every Thursday during lunch. The topics vary from week to week, but the intention is to inspire exchanges amongst our staff. Today's discussion group was presented by Dr. Sui Huang – our resident theorist, who always poses just the right question to provoke thought…
Read More
-
Melding ISB and FHCRC Brain Power for Cancer Research
(Photo above: ISB’s Dr. Ilya Shmulevich describes his lab’s work in The Cancer Genome Atlas project and how ISB and FHCRC could collaborate.) Big health challenges require big science. Cancers are prime examples of overwhelmingly complex diseases that need the power of a cross-disciplinary, systems biology approach to decipher the underlying dysfunctional gene networks in order to find ways to prevent and manage the diseases and develop more effective therapies….
Read More -
ISB In the News: NIH, Viral Networks and Systems Biology
Emily Carlson and Sharon Reynolds, of the National Institutes of Health/NIGMS, posted a story on NIGMS's Inside Life Science as well as on Livescience.com on how systems biology is a powerful approach to studying biological networks. The article included comments from ISB scientist Aaron Brooks and senior research engineer Chris Lausted who created a network activity that they presented during the USA Science & Engineering Festival in Washington D.C. on…
Read More -
It’s National Cancer Research Month: How To Help
May has been designated "National Cancer Research Month" and we'd like to share a little about how ISB is using the systems biology approach to tackle some of the complexities of researching cancers. You can read our four-part series on how ISB's pioneering systems biology has made an impact and continues to clear new pathways for the cancer research field. Please visit aacr.org to learn more about NCRM. Support ISB's…
Read More
-
In Cancer Research, It’s HOW That Matters
By Martin Shelton, Theo Knijnenburg and Joseph Zhou ISB Editorial Board Members The oldest existing record of cancer occurs in a 4000-year-old Egyptian papyrus. It describes, in detail, a woman with symptoms eerily similar to those of modern breast cancer patients. As for the prescribed treatment, there was simply this statement: “No cure.” Sadly, this short and assertive conclusion remains true. According to the American Cancer Society’s annual cancer statistics…
Read More -
Cancer Detection: A Systems Biology Approach
By Martin Shelton ISB Editorial Board Member With the exception of cancers of the skin, mouth, and blood, it is difficult to detect cancer by sight or with a routine health screen. The natural variety that exists at the cellular level — even within cells of the same type — challenges our ability to differentiate healthy tissue from diseased. This variety, what biologists call heterogeneity, means that equally healthy cells…
Read More -
Cancer Stratification: A Systems Approach
By Theo Knijnenburg ISB Editorial Board Member When a patient receives a diagnosis of breast cancer, it’s a specific subtype of breast cancer, such as invasive ductal carcinoma. Each subtype is characterized by the shape and location of the tumor, its growth progression, prognosis and treatment. The ability to stratify, or group, cancer patients based on the specific characteristics of their cancer type, is the first step toward personalized cancer…
Read More
-
Cancer Treatment: A Systems Approach
By Sui Huang and Joseph Zhou, ISB Editorial Board Members Cancer cells, for decades regarded as a uniform mass of identical (“clonal”) cells, are not like the soldiers of a traditional army, trained to act and respond in unison. Cancer cells, even within a genetic clone, express enormous individuality akin to guerrilla fighters, each with unique strengths, weaknesses and distinct behaviors. Therefore, they do not respond to an attack from…
Read More -
ISB Systems Biology Symposium Speaker Videos Now Available
ISB held its 13th Annual International Symposium: Systems Biology & Cancers on April 13-14. Please read more about our speakers and program. If you weren't able to attend or would like to refresh your memory of the talks, we have made a selection of the presentations available to view below. Or visit the playlist on ISB's YouTube channel.
Read More -
ISB at USA Science and Engineering Festival
ISB scientists Aaron Brooks (Baliga Lab) and Martin Shelton (Hood Lab) attended the USA Science & Engineering Festival in Washington D.C. on April 26-27. They, and ISB senior research engineer, Chris Lausted, developed an interactive network activity involving circuit boxes that represent nodes and fiber optic cables to connect them. The project and trip to D.C. were supported by funds through NIH/NIGMS and ISB’s Center for Systems Biology. From Brooks:…
Read More
-
ISB’s Annual Symposium
ISB held its 13th Annual International Symposium: Systems Biology & Cancers From Big Data to Personalized Treatment on April 13-14, 2014. Visit symposium.systemsbiology.net for details. Visit the gallery for images. Or visit the video playlist on ISB’s YouTube channel.
Read More -
Innovation Game Changer: Lee Hood
Dr. Lee Hood appeared in a video series produced by World Free From Cancer and Value of Innovation about five "game changers" who will help make this a cancer-free world.
Read More -
NIH Awards $45M to Alzheimer’s Research
The National Institutes of Health announced $45 million in grants to support several research groups that are focused on Alzheimer's prevention. ISB's Price Lab will be working with the University of Florida to use systems biology to identify new therapeutic targets in the innate immune system. The systems approach, which ISB pioneered, allows scientists to integrate and analyze disparate data (genome, gene expression, pathology) in order to find the molecular…
Read More
-
Collaboration: $16.6M TB Grant
ISB will collaborate with Seattle BioMed and ETH Zurich on a $16.6 million tuberculosis grant from the National Institutes of Health. Seattle BioMed issued this press release today: FOR IMMEDIATE RELEASE SEATTLE, AUG. 15 — Seattle BioMed has been awarded a grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, that will take a comprehensive systems approach to the problem of tuberculosis…
Read More -
It Takes A System To Know A System
Figure depicting cross-disciplinary collaborations among lab groups and usage of technologies housed in ISB’s core facilities. In August, ISB learned that our National Center for Systems Biology was renewed for $13.7 million over the next five years. This is no small feat given that only two National Centers were funded in this round and that there’s fierce competition for diminishing government grants. Here’s how your tax dollars are being put…
Read More -
ISB Co-Authored Nature Paper Featured in the New York Times
The Ilya Shmulevich Group at ISB has been participating in The Cancer Genome Atlas (TCGA) project as a Genome Data Analysis Center. The first paper resulting from the main phase of the TCGA project – "Comprehensive molecular characterization of human colon and rectal cancer" – was published in the July 19, 2012, issue of Nature and also featured on the front page of the New York Times. ISB teamed up…
Read More
-
ISB Featured in Google I/O Conference Keynote
We were very excited to watch the live stream of the keynote from the Google I/O conference today, because it featured work from ISB's Shmulevich Lab, which is one of a group of research organizations that has been working on The Cancer Genome Atlas (TCGA). To help visualize the TCGA data, the lab created the Cancer Regulome Explorer using Google App Engine and Google Compute Engine. Google Compute Engine is…
Read More